OBSV News and Press, ObsEva SA From 01/14/21

Trending Penny Stocks To Watch For The End Of The Week As we inch further into 2021, investors continue to focus on penny stocks . But, if this year has shown us anything, it’s that volatility and speculation are both very high. During this week, several factors have been imp...

Gainers: [[OBSV]] +33%. [[DBVT]] +28.1%. [[TUFN]] +21.8%. [[BB]] +17.2%. [[PPIH]] +13.4%.Losers: [[EAF]] -5%. [[MIK]] -4.4%. [[DOGZ]] -3.9%. [[WBAI]] -3.5%. [[LCI]] -3.2%. For further details see: BB, LCI, OBSV and MIK among after-hours movers

ObsEva ([[OBSV]] -4.5%) has announced validation of European marketing application seeking approval for Yselty (linzagolix) for the Treatment of uterine fibroids.The Yselty Europe application is based on positive data from the Phase 3 PRIMROSE 1 and PRIMROSE 2 studies. The company i...

- European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021 - Phase 3 EDELWEISS 3 (Conducted in Europe and US) Study of Yselty for Treatment of Endometriosis is Progressing as Planned; Primary Endpoint Readout Expected 4Q 2021 - Phase 3 ...

Geneva, Switzerland and Boston, MA – January 7, 2021 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will be participating...

ObsEva SA (OBSV) appoints David Renas as Chief Financial Officer and member of the company’s Executive Committee. He will be based in the U.S.The move is effective today.David Renas has over 30 years of financial and legal experience, including 15 years within the pharmaceutical and li...

Geneva, Switzerland and Boston, MA – January 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the appointment of Davi...

Immutep (IMMP) +132% after breast cancer trial shows promising survival data.Greenwich LifeSciences (GLSI) +57%.UTStarcom Holdings (UTSI) +50%.Panbela Therapeutics (PBLA) +46%.Leju Holdings (LEJU) +38%.SELLAS Life Sciences (SLS) +36%.ClearOne (CLRO) +35% to expand its footprint in M...

ObsEva (OBSV) announces topline 52-week PRIMROSE 1 and 76-week PRIMROSE 2 results of Yselty (linzagolix), in development for the treatment of women with heavy menstrual bleeding due to uterine fibroids. The Week 52 PRIMROSE 1 results showed that continued treatment with Yselty led to sustaine...

PRIMROSE 1 52-week results confirm the sustained efficacy and continued safety of linzagolix (Yselty ® ), with a potential best-in-class high-dose option (200 mg with add-back therapy [ABT]) Show the unique low-dose option (100 mg without ABT) has the potential to add...